Product image of Nulojix (Belatacept) supplied by GNH India

Nulojix

Active Ingredient:
Belatacept
Origin:
EU

Nulojix (Belatacept)

Belatacept, the active ingredient in Nulojix, is an immunosuppressant presented as a 500 mg/10 ml solution for intravenous use. It is used to prevent organ rejection in adult kidney transplant recipients. GNH India supplies Nulojix as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals and transplant centres worldwide.

GNH India supplies Nulojix as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals and transplant centres worldwide.

Manufacturer / TM Owner

Bristol-Myers Squibb Pharma Eeig

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Nulojix is an immunosuppressive agent indicated for specific transplant‑related pathways.

  • Kidney transplantation: helps prevent acute cellular and antibody‑mediated rejection in adult recipients.
  • Maintenance therapy: used as part of a long‑term regimen to sustain graft function after the initial post‑transplant period.
  • Combination therapy: administered with other immunosuppressants such as mycophenolate mofetil and corticosteroids to enhance overall efficacy.

How It Works

  • Belatacept is a selective costimulation blocker that binds to CD80 and CD86 on antigen‑presenting cells, preventing their interaction with CD28 on T‑lymphocytes. This inhibition blocks the necessary second signal for full T‑cell activation, thereby reducing the immune response that can lead to organ‑rejection episodes.

Side Effects

Adverse reactions to belatacept may vary in frequency and severity.

Common Side Effects

  • Headache
  • Nausea
  • Hypertension
  • Peripheral edema
  • Upper respiratory tract infection
  • Fatigue

Serious or Rare Side Effects

  • Post‑transplant lymphoproliferative disorder (PTLD)
  • Severe infections, including opportunistic pathogens
  • Malignancies such as skin cancer
  • Progressive multifocal leukoencephalopathy (PML)
  • Anaphylaxis or severe hypersensitivity reactions

Precautions & Warnings

When using belatacept, clinicians should consider several safety measures.

  • Infection risk: monitor for signs of bacterial, viral, or fungal infections.
  • Malignancy monitoring: conduct regular skin examinations and cancer screenings.
  • Vaccination: avoid live vaccines during treatment.
  • Renal function: assess kidney function regularly, especially during the early post‑transplant period.
  • Pregnancy and lactation: weigh potential benefits against risks; use only if clearly needed.
  • Store at 2‑8°C: keep refrigerated, protect from light, do not freeze or shake.

Avoid Interactions

Belatacept may interact with other medications that affect immune function or infection risk.

Major Interactions (Avoid)

  • Live vaccines: may cause severe infection due to immunosuppression.
  • Strong immunosuppressants (e.g., high‑dose steroids): increase risk of serious infections.

Moderate Interactions (Monitor Closely)

  • Antiviral agents (e.g., ganciclovir): may require dose adjustments.
  • Antifungal agents (e.g., fluconazole): monitor for additive immunosuppressive effects.
  • Antibiotics (e.g., trimethoprim‑sulfamethoxazole): watch for heightened infection risk.
  • Cytokine‑targeted therapies: may alter immune response dynamics.
  • Vaccines requiring adjuvants: assess timing relative to belatacept dosing.

Frequently Asked Questions

Nulojix (belatacept) is prescribed to prevent acute rejection and to maintain graft function in adult kidney transplant recipients. It is used as part of a post‑transplant immunosuppressive regimen, often together with other agents such as mycophenolate mofetil and corticosteroids.

Belatacept blocks the costimulatory signal required for full T‑cell activation by binding to CD80 and CD86 on antigen‑presenting cells, preventing their interaction with CD28 on T‑lymphocytes. This selective inhibition reduces the immune response that can lead to organ rejection.

The dosing regimen for Nulojix is individualized by the transplant physician based on the patient’s clinical status, weight, and time since transplantation. The prescriber determines the appropriate dose and infusion schedule.

Safety data for belatacept in pregnancy and lactation are limited. It should only be used if the potential benefits justify the potential risks to the fetus or infant, and the decision should be made by the treating physician.

To order Nulojix, submit an enquiry on the product page at gnhindia.com with the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed) and import documentation.

Compared with calcineurin inhibitors such as tacrolimus, belatacept offers a different mechanism—costimulation blockade—potentially reducing nephrotoxicity. However, it may carry a higher risk of certain infections and post‑transplant lymphoproliferative disorder, requiring careful patient selection.

Nulojix should be stored at 2‑8 °C (refrigerated), protected from light, and must not be frozen or shaken. Keep the product in its original packaging until ready for use.

Nulojix is given as an intravenous infusion. The initial dosing schedule typically includes more frequent infusions during the first weeks post‑transplant, followed by maintenance infusions at longer intervals, as directed by the transplant specialist.

Serious risks include post‑transplant lymphoproliferative disorder (PTLD), severe opportunistic infections, certain malignancies, and rare neurological conditions such as progressive multifocal leukoencephalopathy (PML). Patients should be monitored closely for these events.

Nulojix is contraindicated in patients with a known hypersensitivity to belatacept or any of its excipients, and it should be avoided in individuals receiving live vaccines or those with uncontrolled active infections.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Belatacept

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT